Does Bristol-Myers Squibb Co. Have Any Fuel Left in its Tank?

An update on my prediction that Bristol-Myers Squibb will outperform in 2014.

Feb 21, 2014 at 2:00PM

Like many endurance or long distance racing sports, a solid strategy often involves patience. Getting out of the gate or off the blocks too quickly can come back to bite the competitor as they run out of juice before they finish. The same analogy can also be used with stocks, especially those with known catalysts in their future. As biotech companies prepare to release important clinical data, investor excitement often pushes stocks up to a point which may not be justified. When that clinical data either disappoints or is delayed, the company's stock often sees a harsh correction. Such has been the case with Bristol Myers Squibb (NYSE:BMY) so far this year, which I believe will be a top performer in 2014.

Can Bristol-Myers Squibb have another great year?
As of Feb 19, my prediction isn't looking so good yet. Just take a look at this chart for year-to-date performances of select large cap pharmaceutical stocks.

BMY Total Return Price Chart

Source: Data by YCharts.

That's Bristol-Myers Squibb bringing up the rear, up just 1.3%. Merck (NYSE: MRK) up 11.5%, Amgen (NASDAQ: AMGN) up 8.86%, Gilead (NASDAQ: GILD) up 10.3%, and even Pfizer (NYSE: PFE) up 3.9% have beaten Bristol this year. Gilead is firing on all cylinders with its recent launch of Sovaldi, which looks to be a potential blockbuster drug for the treatment of hepatitis C. Merck is finally getting recognition for MK-3475, a PD-1 inhibitor that will directly compete with Bristol's most important pipeline asset in nivolumab. Meanwhile, Pfizer recently had positive data with its most important pipeline candidate in palbociclib (also with Breakthrough Designation). There is still a ways to go this year, and lots of data to digest, but this prediction is not holding up so far.

So what is going on with Bristol-Myers Squibb?
My prediction is predicated on Bristol's unique position to be the leader in immuno-oncology (IO), or drugs that cause the immune system to recognize and fight cancer. One of the major cornerstones of its pipeline is a drug called nivolumab, which inhibits the programmed death 1 (PD-1) checkpoint pathway. Solid tumors exploit this pathway and ultimately evade detection by T-cells, which have the ability to keep cancer in check. Nivolumab is designed to block this escape and allow the body to use its own immune system to fight and kill tumors. Bristol's lead in the immuno-oncology space is going to be challenged by several competitors, though. The lead appeared to narrow when Merck decided to file its own PD-1 inhibitor, MK-3475, for approval with the FDA on a rolling submission basis in melanoma, which could slow sales of Yervoy. Roche also has a compound, RG-7446, that targets the PD-L1 ligand that could also be a competitive threat and Novartis just made a small acquisition of CoStim Pharmaceuticals, a private company with pre-clinical compounds in immuno-oncology, including a PD-1 inhibitor.

The potential for IO drugs is huge and takes a vastly different approach than traditional small molecule drugs, which include targeted therapies or even traditional chemotherapies. Immuno-oncology has been estimated by some to be a $30 billion market in the not too distant future. Bristol already has one approved immuno-oncology drug in Yervoy for metastatic melanoma which generated $960 million last year and a number of pipeline candidates in development, most importantly of which is nivolumab. At present Bristol has more than 25 clinical trials studying this drug.

Am I wrong about Bristol?
Well, it is still early in the year and there are a number of catalysts to look forward to that could get Bristol-Myers back on track. However, I did overlook the stock's outstanding performance last year. Bristol gained nearly $30 billion in market value and was up nearly 70% in 2013, so it appears that investors have given plenty of credit to Bristol's late stage pipeline. The biggest indications for nivolumab include lung cancer, melanoma, and kidney cancer, and its stock performance this year will largely depend on the outcome of its lung cancer trials, which could be the first approved indication for nivolumab. We will know a lot more in June when BMY presents data at the American Society of Clinical Oncology (ASCO) conference.

Outside of nivolumab and Yervoy, it is important to assess Bristol's currently approved drugs to model out its potential revenue growth. Recently approved Eliquis for reducing stroke in patients with atrial fibrillation should have decent growth as should Sprycel for CML and Orencia for rheumatoid arthritis. It would also not surprise me to see Bristol make a fairly large acquisition this year  to continue to boost its pipeline in oncology after recently divesting its diabetes franchise to AstraZeneca. On the flipside, expiring patents could pose a challenge in the near term. Patents on Sustiva (HIV) and Baraclude (hepatitis B) expire in 2014, Abilify (depression) and other Baraclude patents expire in 2015, and Reyataz (HIV) has patents which expire in 2017. These amount to $6 billion worth of revenues that could be at risk to generics in the next 3-4 years, obviously a large hole to make up. In fact, average estimates by analysts have BMY revenues declining slightly this year and next year. As such, it is critical for Bristol to have positive data regarding nivolumab this year and get revenue growth back on track in 2016.

It is still early in the year and Bristol has plenty of time to make up ground. ASCO in June will be very important for the company and go a long way in determining how it ultimately performs this year. If the nivolumab data and an exciting acquisition ultimately prove out, Bristol-Myers could once again outperform. I will be sure to circle back to this name in June, if not earlier.

Where to look for the most robust dividend stocks the market has to offer
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it’s true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor’s portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Chris Ahlstrand owns shares of Bristol-Myers Squibb Co. and Merck. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers